About 5 000 reports

EXECUTIVE SUMMARY ##.

  • Cancer
  • Lymphoma
  • APAC
  • World
  • Market Shares
  • Tests for lymphoma
  • Diagnosis of lymphoma

HL is one of the curable forms of lymphoma.

  • Healthcare
  • Forecast
  • Celgene Corporation
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited

You can request one free hour of our analyst’s time when you purchase this market report.

  • Lymphoma
  • Therapy
  • World
  • Market Size

Hoffmann-La Roche • Merck Sharp & Dohme • Novartis • Spectrum Pharmaceuticals About Burkitt Lymphoma Burkitt Lymphoma is one of the rare types of B-cell non-Hodgkin’s lymphoma.

  • Healthcare
  • Lymphoma
  • Therapy
  • World
  • Market Size
  • VII. LYMPHOMA
  • Lymphoma Treatment Drugs Markets in China

Cytotoxic antibiotics and related drugs is one important Lymphoma Treatment Drugs in China.

  • Healthcare
  • China
  • Shandong Luoxin Pharmacy Stock Co., Ltd.
  • Shenzhen Main Luck Pharmaceuticals Inc.
  • Zhejiang Hisun Pharmaceutical Co., Ltd.
  • LYMPHOMA TREATMENT DRUGS INDUSTRY ASSESSMENTS
  • LYMPHOMA TREATMENT DRUGS INDUSTRY ASSESSMENTS

Cytotoxic antibiotics and related drugs is one important Lymphoma Treatment Drugs in China.

  • Healthcare
  • China
  • Beijing Wintic Pharma Co., Ltd
  • Pfizer Inc.
  • Shandong Luoxin Pharmacy Stock Co., Ltd.

You can request one free hour of our analyst’s time when you purchase this market report.

  • Lymphoma
  • Therapy
  • World
  • Market Size

The 2020-2025 World Outlook for Lymphoma Therapeutics ## INTRODUCTION ##. ## OVERVIEW ##. ## WHAT IS LATENT DEMAND AND THE P. I. E.?

  • Cancer
  • Healthcare
  • Lymphoma
  • Pathology
  • Demand

Global Diffuse Large B Cell Lymphoma Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024 ##.

  • Healthcare
  • Lymphoma
  • Therapy
  • World
  • Market Size

NHL: Follicular Lymphoma Forecast and Market Analysis (FL) to 2026 CONTENTS ## FORECAST: FOLLICULAR LYMPHOMA (Published on ## January 2019) ## OVERVIEW ## RECENT FORECAST UPDATES ## MARKET DYNAMICS ## FORECAST AND FUTURE TRENDS ## MARKET DEFINITION AND METHODOLOGY ## PRIMARY

  • Healthcare
  • Lymphoma
  • European Union
  • Japan
  • United States

This cancer is the most common type of non-Hodgkin’s lymphoma (NHL), accounting for about one-third of all newly diagnosed cases.

  • Healthcare
  • European Union
  • Japan
  • United States
  • Demand

NHL: Follicular Lymphoma Forecast and Market Analysis to 2025 TABLE OF CONTENTS Forecast, Treatment, Epidemiology Datapacks included) & nbsp; ## FORECAST: FOLLICULAR LYMPHOMA (Published on ## April 2016) ## OVERVIEW ## EXECUTIVE SUMMARY ## MARKET OVERVIEW AND TRENDS ## METHODOLOGY

  • Healthcare
  • Lymphoma
  • European Union
  • Japan
  • United States

The disease often initially responds to treatment, but disease relapse inevitably occurs within ##–## years.

  • Healthcare
  • Lymphoma
  • European Union
  • Japan
  • United States

This cancer is the most common type of non-Hodgkin’s lymphoma (NHL), accounting for about one-third of all newly diagnosed cases.

  • Healthcare
  • Lymphoma
  • European Union
  • Japan
  • United States
  • Ann Arbor staging used in lymphoma
  • Pipeline: Diffuse Large B-Cell Lymphoma

PLoS One, ##(##), e##.

  • Healthcare
  • European Union
  • Japan
  • United States
  • Roche Group
  • EPIDEMIOLOGY: FOLLICULAR LYMPHOMA
  • Epidemiology: Follicular Lymphoma

NHL: Follicular lymphoma Disease Coverage | Forecast: Follicular Lymphoma DMKC## US ## ## ## ## ## ## ## ## ## ## Japan ## ## ## ## ## ## ## ## ## ## France ## ## ## ## ## ## ## ## ## ## Germany ## ## ## ## ## ## ##

  • Healthcare
  • European Union
  • Japan
  • North America
  • United States
  • FORECAST: MANTLE CELL LYMPHOMA
  • EPIDEMIOLOGY: MANTLE CELL LYMPHOMA

Blood, ##(##), ##-## < DOI> ##. ##/ blood-2005-##-##< / DOI>.

  • Healthcare
  • United States
  • Celgene Corporation
  • Pfizer Inc.
  • Roche Group

There are several drug approvals for lymphoma involving drug targets as antibody-drug conjugates, programmed death-## receptor/ programmed death ligands and microtubules, among others.

  • Cancer
  • Healthcare
  • Leukemia
  • Pathology
  • World

The high incidence of various types of leukemia in pediatric patients is expected to be one of the major drivers of the global blood cancer therapeutics market during the forecast period.

  • Cancer
  • Healthcare
  • Pathology
  • World
  • Forecast

There are various types of B-cell NHL including Burkitt lymphoma, chronic lymphocytic leukemia (CLL), follicular lymphoma, and mantle cell lymphoma.

  • Cancer
  • Lymphoma
  • Pathology
  • World
  • RISK FACTORS AND COMORBIDITIES FOR PROSTATE CANCER
  • PROVIDES AN ASSESSMENT OF ASTRAZENECA'S PCA PORTFOLIO.

BAY-##, AN ORAL ATR INHIBITOR, IS BEING INVESTIGATED IN A PHASE I STUDY (BAYER, NCT##) IN SOLID TUMORS (INCLUDING PCA) AND LYMPHOMAS.

  • Healthcare
  • East Asia
  • United States
  • Forecast
  • Pfizer Inc.
  • MM, Sources Used to Forecast the Diagnosed Incident Cases of MM
  • Year

The Leukemia and Lymphoma Society (2015) Myeloma.

  • Cancer
  • Healthcare
  • Japan
  • United States
  • Forecast

Blood testing for oncology is one of the most rapidly developing fields in the market, with the higher incidence of cancers and the development of companion diagnostics and precision medicine for the treatment of these diseases contributing to growth.

  • Diagnostics
  • Healthcare
  • World

Betalutin

8770 10000 7800

Betalutin CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Betalutin : NHL: Follicular lymphoma (FL) LIST OF FIGURES ## Figure ##: Betalutin for follicular lymphoma – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary of Betalutin for

  • Cancer
  • Healthcare
  • Lymphoma
  • European Union
  • United States

Aliqopa

8770 10000 7800

Aliqopa CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Aliqopa : NHL: Follicular lymphoma (FL) LIST OF FIGURES ## Figure ##: Aliqopa for follicular lymphoma – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary of Aliqopa for follicul

  • Healthcare
  • Lymphoma
  • European Union
  • Japan
  • United States

INCB050465

8770 10000 7800

INCB## CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## INCB## : NHL: Follicular lymphoma (FL) LIST OF FIGURES ## Figure ##: INCB## for follicular lymphoma – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary of INCB##

  • Cancer
  • Healthcare
  • Lymphoma
  • United States
  • Forecast

umbralisib

8770 10000 7800

umbralisib CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## umbralisib : NHL: Follicular lymphoma (FL) ## umbralisib : NHL: Diffuse large B-cell lymphoma (DLBCL) LIST OF FIGURES ## Figure ##: Umbralisib for follicular lymphoma – SWOT analysis ## Figure

  • Cancer
  • Healthcare
  • Lymphoma
  • European Union
  • United States

lisocabtagene maraleucel CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## lisocabtagene maraleucel : NHL: Follicular lymphoma (FL) ## lisocabtagene maraleucel : NHL: Diffuse large B-cell lymphoma (DLBCL) LIST OF FIGURES ## Figure ##: Lisocabtagene maraleucel for

  • Healthcare
  • Lymphoma
  • European Union
  • Japan
  • United States

Yescarta

8770 10000 7800

In heavily pretreated patients, Yescarta treatment resulted in strong and durable response rates, as demonstrated in the ZUMA-## trial.

  • Healthcare
  • Medical Biotechnology
  • European Union
  • Japan
  • United States
  • Estimated New Cases of Cancer in the United States, By Type 2018 (In %)
  • U.S PROTON THERAPY MARKET

For sarcomas and lymphomas, proton therapy may also deliver less radiation to the heart, lungs, and intestines.

  • Healthcare
  • World
  • Market Size
  • Hitachi, Ltd.
  • Varian Medical Systems, Inc.